Viewing data from:

MILRINONE LACTATE

ANDA

MILRINONE LACTATE | A075530 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Milrinone Lactate (2023)

Total Spending

$241K

Total Claims

1,244

Beneficiaries

Avg Cost/Unit

$0.71

Spending Trend

$3.4M(2019)→$2.8M(2020)→$1.9M(2021)→$1.0M(2022)→$241K(2023)

YoY Change:-68.3%

5yr CAGR:-30.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs2 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

FARMHISPANIA SAMILRINONE

DMF 143191999

W R GRACE AND CO -CONNMILRINONE USP

DMF 143751999

HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO LTDMILRINONE

DMF 197262006

EMCURE PHARMACEUTICALS LTDMILRINONE USP

DMF 299052015

BOEHRINGER INGELHEIM CHEMICALS INCInactiveMILRINONE

DMF 140231999

SAI LIFE SCIENCES LTDInactiveMILRINONE

DMF 197092006

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 9, 2004	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 1MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: May 28, 2002

No patent or exclusivity listings for this strength.